George Gauthier - Apr 4, 2023 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Role
Chief Commercial Officer
Signature
/s/ Fred Schwarzer, by power of attorney
Stock symbol
IGMS
Transactions as of
Apr 4, 2023
Transactions value $
-$11,781
Form type
4
Date filed
4/6/2023, 09:39 PM
Previous filing
Mar 16, 2023
Next filing
Apr 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGMS Common Stock Award $0 +16.3K +87.54% $0.00 34.8K Apr 4, 2023 Direct F1
transaction IGMS Common Stock Sale -$11.8K -935 -2.69% $12.60 33.9K Apr 5, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IGMS Stock Option (right to buy) Award $0 +32.5K $0.00 32.5K Apr 4, 2023 Common Stock 32.5K $12.86 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-fourth of the RSUs shall vest on March 12, 2024 and each one-year anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date.
F2 The sale reported by the Reporting Person was effected pursuant to a Rule 10b5-1 trading plan, entered into on December 29, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
F3 1/48 of the shares subject to the option shall vest on April 12, 2023 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date.